Fecal carriage of carbapenemase and AmpC-β-lactamase producers among extended spectrum β-Lactamase-producing E. coli and Klebsiella spp. isolates in patients attending hospitals
Zakaria Garba(Université Joseph Ki-Zerbo), Halidou Tinto(Institut de Recherche en Sciences de la Santé), Georges Somé(Institut de Recherche en Sciences de la Santé), Nicolas Barro(Université Joseph Ki-Zerbo), Namwin Siourimè Somda(Centre National de la Recherche Scientifique et Technologique), Lassana Sangaré(Université Joseph Ki-Zerbo), Isidore Juste O. Bonkoungou(Université Joseph Ki-Zerbo), Hamtandi Magloire Natama(Research Institute of Health Sciences)
Cited by 6
Related Papers
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
|The Lancet|2021|457
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
|The Lancet|2024|345
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial
|The Lancet Infectious Diseases|2022|285
Genomic and environmental risk factors for cardiometabolic diseases in Africa: methods used for Phase 1 of the AWI-Gen population cross-sectional study
|Global Health Action|2018|146
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
|The Lancet Infectious Diseases|2024|48